Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 14, 2022, the Company and David E. Lazar, the Company's Chief
Executive Officer, entered into an Employment Agreement (the "Lazar Agreement"),
pursuant to which the Company hired Mr. Lazar to serve as the Company's Chief
Executive Officer, effective August 16, 2022.
Prior to being named Chief Executive Officer of the Company, Mr. Lazar, age 32,
has served as the Chief Executive Officer of Custodian Ventures LLC, a company
which specializes in assisting distressed public companies through
custodianship, since February 2018, and Activist Investing LLC, an actively
managed investment fund, since March 2018. Mr. Lazar served as Managing Partner
at Zenith Partners International Inc., a boutique consulting firm, from July
2012 to April 2018.
Pursuant to the terms of the Lazar Agreement, Mr. Lazar will be paid a base
salary of $406,000 per year, and will participate in the Company's equity
incentive plan (the "Plan"). Due to the Company's current liquidity situation,
approximately 70% of Mr. Lazar's compensation will be deferred until such time
as the Compensation Committee determines that the Company has sufficient
liquidity to pay the full salary. Mr. Lazar will be eligible to receive an
annual bonus, with a target of fifty percent (50%) of his base salary. In
addition, Mr. Lazar will be eligible for three performance bonuses on an annual
basis, payable in (i) cash and/or (ii) restricted stock under the Plan, each
equal to fifty percent (50%) of his base salary, which shall be dependent on the
achievement by the Company of certain milestones. Furthermore, in the event of a
Change of Control (as defined in the Lazar Agreement), the Company shall pay Mr.
Lazar a bonus equal to three percent (3%) of the increased valuation of the
surviving corporation resulting from such Change of Control. The foregoing
summary is qualified in its entirety by reference to the Lazar Agreement
attached hereto as Exhibit 10.1 and incorporated by reference.
Item 8.01. Other Events.
On December 15, 2022, the Company issued a press release announcing the
Company's entry into a nonbinding letter of intent to acquire a leading
developer of personal air and land vehicles specializing in urban air mobility.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
10.1 Employment Agreement, dated December 14, 2022, between Titan
Pharmaceuticals, Inc. and David E. Lazar.
99.1 Press Release of Titan Pharmaceuticals, Inc. dated December 15,
2022.
104 Cover Page Interactive Data (embedded within the Inline XBRL
document).
1
© Edgar Online, source Glimpses